Genexine (South Korea)
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)< Genexine’s immune-oncology experts with extensive experience in academic research focuses on the research and development of novel drugs.
Basic Information
- Category: business
- Founded: 1999
- Headquarters: Seongnam-si
- Website: http://www.genexine.com/
Documented Facts
- Email: bd@genexine.com (No linked source recorded for this statement.)
- Founded: 1999 (No linked source recorded for this statement.)
- Website: http://www.genexine.com/ (No linked source recorded for this statement.)
- Headquarters: Seongnam-si (No linked source recorded for this statement.)
- Founded by: Youngchul Sung (No linked source recorded for this statement.)
- Country: South Korea (No linked source recorded for this statement.)
Evidence and Sources
- Genexine (South Korea) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Genexine (South Korea).
- Canonical profile: https://brandsource.ai/brands/genexine-south-korea
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/genexine-south-korea/json-ld
- Citation profile API: https://brandsource.ai/api/brands/genexine-south-korea/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (86/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)< Genexine’s immune-oncology experts with extensive experience in academic research focuses on the research and development of novel drugs.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 6 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.